Eficacia y Seguridad Multidominios de Guselkumab a lo largo de 1 Año en Pacientes con Artritis Psoriásica Activa con y sin Exposición a Inhibidores del Factor de Necrosis Tumoral: Análisis del Ensayo de Fase 3, Aleatorizado, Controlado con Placebo DISCOVER-1
ACR Open Rheumatol. 2023 doi: 10.1002/acr2.11523
TNF inhibitors (TNFi) are one main mode of therapy in patients with PsA who fail to respond to csDMARDs. However, they have a primary treatment failure rate of 40% and only a modest target of ≥20% ACR20 response. The objective of this study was to evaluate efficacy and safety of guselkumab, interleukin-23 inhibitor in the DISCOVER-1 study with active PsA patients by prior use of TNFi.